Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia With Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

Program Description

Hyperkalemia is an electrolyte disorder that can result in serious cardiac complications. It can occur in the inpatient or outpatient setting and is more likely to occur in patients with comorbidities such as chronic kidney disease heart failure, hypertension, diabetes, or other cardiovascular conditions especially when receiving renin-angiotensin-aldosterone system inhibitors. Hyperkalemia increases morbidity, mortality, and health care costs in these patient populations. Although potassium binders have been available for decades, traditional therapies such as sodium polystyrene sulfonate are limited by safety and tolerability concerns. Newer agents offer improved efficacy and safety profiles, making it essential for managed care pharmacists to understand their role in both acute and chronic hyperkalemia management. This activity will explore treatment options for acute and chronic hyperkalemia including real world use and practice patterns, identify the economic challenges associated with the condition, and review approaches to for developing cost-effective, patient-centered coverage policies. With a greater understanding of hyperkalemia and the treatment landscape, managed care pharmacists can expand patient access to appropriate treatments, maximize patient outcomes, and improve health care resource utilization.

Target Audience: Managed care pharmacists

Type of Activity: Application

Release date: November 21, 2025

Expiration date: November 21, 2026

Learner level: Foundational, Intermediate

Time to complete activity: 1.0 hour

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the etiology and patient populations at higher risk for the development of hyperkalemia and its related complications if left untreated
• Analyze available efficacy and safety data for newer oral potassium-binding medications for the swift and long-term management of hyperkalemia
• Examine approaches managed care pharmacists can employ to ensure cost-effective, patient-centered treatment plans

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-381-H01-P. The activity is available for CE credit through November 21, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Joanna Hudson, PharmD, BCPS, FASN, FCCP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Rose Buszka, PharmD, BCPS, CHCP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms